Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback